Needham Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44

Benzinga Newsdesk www.benzinga.com Positive 51.3%

Neg 0% Neu 0% Pos 51.3%

Needham analyst Gil Blum initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $44.